Select Page

GSK’s (GlaxoSmithKline) and Vir Biotechnology’s antibody treatment for COVID-19, Sotrovimab has been approved in Japan, Health Minister Norihisa Tamura announced this week. Aiming to treat mild to moderate coronavirus cases, GSK’s antibody treatment does not require oxygen supplementation. GSK’s application for approval is set to be fast-tracked this month.

Read more here.

More on: